TMPRSS2 and metabolic dysfunction-associated steatotic liver disease: Interestingly, NAFLD patients who experienced fever and myalgia due to COVID-19 disease showed a lower expression of TMPRSS2 protein in the liver (3.56 ± 0.21 vs. 1.54 ± 0.43, p = 0.0038), Supplementary Figure S1e.